A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

Inclusion Criteria * Participants must have measurable disease. * Participants must have previously been treated with certain defined anti-cancer therapies and their disease must have come back or must have not responded to the previous or last treatment. * Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Participants that have histologically confirmed Follicular Lymphoma (FL) (Grade 1, 2, or 3a) corresponding to the most recent relapse prior to screening. * Participants that have Relapsed or refractory FL, as assessed by the Investigator. * Participants that have received at least one prior line and no more than three prior lines of systemic therapy including a combination of an anti-CD20 antibody and an alkylating agent. * Participants that received one prior line of systemic therapy are eligible if they present with high risk features. Exclusion Criteria * Participants must not have any history of heart problems. * Participants must not have any bleeding disorders. * Participants must not have any Central Nervous System involvement by Follicular Lymphoma or other brain conditions. * Other protocol-defined Inclusion/Exclusion criteria apply.